RSSParkinson’s disease

Abnormality of Contingent Negative Variation Correlates with Parkinson’s Disease Severity

Abnormality of Contingent Negative Variation Correlates with Parkinson’s Disease Severity

| July 1, 2022

by Plamen Tzvetanov, MD, Phd, DSc, FRCP; Ivan Lisichkov, MD, PhD; Rossen T. Rousseff MD, PhD; Vishwajit Hegde, MD, FRCP; and Sergey Kostadinov, MD, PhD Prof. Tzvetanov is with the Department of Clinical Neurophysiology, Broomfield Hospital Mid Essex Hospital Trust in Broomfield, United Kingdom. Dr. Lisichkov is with the Department of Neurology, Multiprofile Hospital for Active Treatment […]

Continue Reading

Pimavanserin in the Treatment of Parkinson’s Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials

Pimavanserin in the Treatment of Parkinson’s Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials

| January 1, 2022

by Zeeshan Mansuri, MD, MPH; Abhishek Reddy, MD; Ramu Vadukapuram, MD; Chintan Trivedi, MD, MPH; and Amy Amara, MD, PhD  Dr. Mansuri is with the Department of Psychiatry, Boston Children’s Hospital/Harvard Medical School in Boston, Massachusetts. Dr. Reddy is with the Department of Psychiatry, Virginia Tech Carilion School of Medicine in Roanoke, Virginia. Dr. Vadukapuram is with […]

Continue Reading

Palmitoylethanolamide/Luteolin as Adjuvant Therapy to Improve an Unusual Case of Camptocormia in a Patient with Parkinson’s Disease:  A Case Report

Palmitoylethanolamide/Luteolin as Adjuvant Therapy to Improve an Unusual Case of Camptocormia in a Patient with Parkinson’s Disease: A Case Report

| October 1, 2021

by Stefania Brotini, MD Dr. Brotini is with the Movement Disorder Center, Department of Neurology, San Giuseppe Hospital in Empoli, Florence, Italy FUNDING: No funding was provided for this study.  DISCLOSURES: The author has no conflicts of interest relevant to the content of this article.  Innov Clin Neurosci. 2021;18(10–12):12–14. ABSTRACT: Background. Camptocormia is a complication in […]

Continue Reading

Letters to the Editor: What About Biomarkers for Parkinson’s Disease?

Letters to the Editor: What About Biomarkers for Parkinson’s Disease?

| January 1, 2021

Dear Editor: Parkinson’s disease (PD) affects over 600,000 patients in the United States; these numbers might double by 2040, as the population of older people increases.1 Diagnostic clues include the signs of resting tremor, bradykinesia, muscle rigidity, and postural imbalance. However, these clinical indicators might be inaccurate much of the time. A low rate of […]

Continue Reading

Effects of Prismatic Lenses on Lateral Axial Dystonia in Parkinson’s Disease: A Pilot Study

Effects of Prismatic Lenses on Lateral Axial Dystonia in Parkinson’s Disease: A Pilot Study

| January 1, 2021

by Michele Meglio, PhD Student; Enrica Olivola, MD, PhD; Marco Santilli, BSC; Francesco Lena, MSC, PhD; Diego Centonze, MD, PhD; Matteo Bologna, MD, PhD; and Nicola Modugno, MD, PhD Dr. Meglio is with IRCCS Neuromed in the Unit of Neuro-Ophthalmology in Pozzilli, Italy; he’s a PhD student in Neuroscience at University of Rome Tor Vergata […]

Continue Reading

Innovative Approaches for Slowing Disease Progression in Parkinson’s Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting

Innovative Approaches for Slowing Disease Progression in Parkinson’s Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting

| January 1, 2020

by Monica Javidnia, PhD; Mark Frasier, PhD; Ira Shoulson, MD; Ibrahim Turkoz, PhD; and Kumar Budur, MD, MS Drs. Javidnia and Shoulson are with the Center for Health + Technology and the Department of Neurology, University of Rochester Medical Center in Rochester, New York. Dr. Shoulson is also with Grey Matter Technologies in Sarasota, Florida. […]

Continue Reading

Correlation Between the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale and Nonmotor Scales in Patients with Parkinson’s Disease

Correlation Between the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale and Nonmotor Scales in Patients with Parkinson’s Disease

| September 1, 2019

by Erika D. Driver-Dunckley, MD; Nan Zhang, MS; Holly A. Shill, MD; Shyamal H. Mehta, MD, PhD; Christine M. Belden, PsyD; Edward Y. Zamrini, MD; Kathryn Davis; Thomas G. Beach, MD, PhD; and Charles H. Adler, MD, PhD Drs. Driver-Dunckley, Mehta, and Adler are with the Department of Neurology of the Parkinson’s Disease and Movement […]

Continue Reading

Hot Topics in Neuroscience: Marijuana for Parkinson’s Disease?

Hot Topics in Neuroscience: Marijuana for Parkinson’s Disease?

| January 1, 2019

by Diksha Mohanty, MD, and Steven Lippmann, MD Dr. Mohanty is Research Scholar and Dr. Lippmann is Emeritus Professor at the University of Louisville School of Medicine in Louisville, Kentucky. Funding: No funding was provided. Disclosures: The authors have no conflicts of interest relevant to the content of this article. Abstract: Marijuana is popular in […]

Continue Reading

Letter to the Editor: Looking Beyond the Obvious: Non-motor Parkinsonism

Letter to the Editor: Looking Beyond the Obvious: Non-motor Parkinsonism

| October 1, 2018

By Shivani Naik, MD; Murali Kolikonda, MD; Shanti Pittampalli, MD; Steven Lippmann, MD Funding/financial disclosures. The authors have no conflicts of interest relevant to the content of this letter. No funding was received for the preparation of this letter. Innov Clin Neurosci. 2018;15(9–10):11–13 Dear Editor: Parkinson’s disease (PD) is second to Alzheimer’s disease as the most common neurodegenerative disease, […]

Continue Reading